9p21 and 13q14 dosages in ependymomas. A clinicopathologic study of 101 cases

Modern Pathology

Volumn 17, Issue 1, 2004, Pages 9-14

  Rajaram, Veena ^a   Leuthardt, Eric C ^a   Singh, Pratima K ^a   Ojemann, Jeffrey G ^a   Brat, Daniel J ^b   Prayson, Richard A ^c   Perry, Arie ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Brain tumor; Ependymoma; FISH; p16 RB; Prognosis; RB pathway; Tumor genetics

Indexed keywords

ADOLESCENT; ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER GRADING; CHILD; CHROMOSOME 13Q; CHROMOSOME 9P; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DEATH; DISEASE COURSE; EPENDYMOMA; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE DELETION; HUMAN; INTRACRANIAL TUMOR; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SPINAL CORD TUMOR; TUMOR GROWTH; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EPENDYMOMA; FOLLOW-UP STUDIES; GENE DELETION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; MIDDLE AGED; NEOPLASM STAGING; RETINOBLASTOMA PROTEIN; SPINAL CORD NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 13444296246     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800029     Document Type: Article

References (37)

1. Fokes Jr EC, Earle KM. Ependymomas: clinical and pathological aspects. J Neurosurg 1969;30:585-594.
2. Mork SJ, Loken AC. Ependymoma: a follow-up study of 101 cases. Cancer 1977;40:907-915.
3. Ross GW, Rubinstein LJ. Lack of histopathological correlation of malignant ependymomas with postoperative survival. J Neurosurg 1989;70:31-36.
4. Schiffer D, Chio A, Giordana MT, et al. Histologic prognostic factors in ependymoma. Childs Nerv Syst 1991;7:177-182.
5. Robertson PL, Zeltzer PM, Boyett JM, et al. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg 1998;88:695-703.
6. Sala F, Talacchi A, Mazza C, et al. Prognostic factors in childhood intracranial ependymomas: the role of age and tumor location. Pediatr Neurosurg 1998;28:135-142.
7. Ernestus RI, Schroder R, Stutzer H, et al. Prognostic relevance of localization and grading in intracranial ependymomas of childhood. Childs Nerv Syst 1996;12:522-526.
8. Horn B, Heideman R, Geyer R, et al. A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. J Pediatr Hematol Oncol 1999;21:203-211.
9. Kovalic JJ, Flaris N, Grigsby PW, et al. Intracranial ependymoma long term outcome, patterns of failure. J Neurooncol 1993;15:125-131.
10. Mansur DB, Michalski JM, Ojemann JG, et al. Long-term results of surgery and post-operative radiation therapy in the curative management of intracranial ependymoma [abstract]. Int J Radiat Oncol Biol Phys 2002;54:204-205.
11. Friede RL, Pollak A. The cytogenetic basis for classifying ependymomas. J Neuropathol Exp Neurol 1978;37:103-118.
12. Bennetto L, Foreman N, Harding B, et al. Ki-67 immunolabelling index is a prognostic indicator in childhood posterior fossa ependymomas. Neuropathol Appl Neurobiol 1998;24:434-440.
13. Korshunov A, Golanov A, Timirgaz V. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. J Neurol Sci 2000;177:72-82.
14. Hamilton RL, Pollack IF. The molecular biology of ependymomas. Brain Pathol 1997;7:807-822.
15. Ebert C, von Haken M, Meyer-Puttlitz B, et al. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol 1999;155:627-632.
16. Lamszus K, Lachenmayer L, Heinemann U, et al. Molecular genetic alterations on chromosomes 11 and 22 in ependymomas. Int J Cancer 2001;91:803-808.
17. Singh PK, Gutmann DH, Fuller CE, et al. Differential involvement of protein 4.1 family members DAL-1 and NF2 in intracranial and intraspinal ependymomas. Mod Pathol 2002;15:526-531.
18. Gutmann DH, Giordano MJ, Fishback AS, et al. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology 1997;49:267-270.
19. Suzuki SO, Iwaki T. Amplification and overexpression of mdm2 gene in ependymomas. Mod Pathol 2000;13:548-553.
20. Mazewski C, Soukup S, Ballard E, et al. Karyotype studies in 18 ependymomas with literature review of 107 cases. Cancer Genet Cytogenet 1999;113:1-8.
21. Tong CY, Zheng PP, Pang JC, et al. Identification of novel regions of allelic loss in ependymomas by high-resolution allelotyping with 384 microsatellite markers. J Neurosurg 2001;95:9-14.
22. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-737.
23. Bouvier-Labit C, Civatte M, Bartoli C, et al. p16INK4a and p19INK4d mRNA expression in neuroglial tumours: correlation with Ki67 proliferation index. Neuropathol Appl Neurobiol 1999;25:408-416.
24. Hirose Y, Aldape K, Bollen A, et al. Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol 2001;158:1137-1143.
25. Perry A, Anderl KA, Borell TJ, et al. Detection of p16, RB, CDK4, and p53 gene deletion/amplification by fluorescence in situ hybridization (FISH) in 96 gliomas. Am J Clin Pathol 1999;112:801-809.
26. Smith JS, Jenkins RB. Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications. Front Biosci 2000;5:213-231.
27. von Deimling A, Fimmers R, Schmidt MC, et al. Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. J Neuropathol Exp Neurol 2000;59:544-558.
28. Reifenberger G, Louis DN. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 2003;62:111-126.
29. Wiestler OD, Schiffer D, Coons SW, et al. Ependymal tumors. In: Kleihues P, Cavenee WK (eds). Pathology and Genetics of Tumours of the Nervous System. World Health Organization Classification of Tumors. IARC Press: Lyon, 2000, pp. 71-81.
30. Perry A, Fuller CE, Banerjee R, et al. Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Biosci 2003;8:1-9.
31. Bortolotto S, Chiado-Piat L, Cavalla P, et al. CDKN2A/p16 in ependymomas. J Neurooncol 2001;54:9-13.
32. Dyer S, Prebble E, Davison V, et al. Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. Am J Pathol 2002;161:2133-2141.
33. Jeuken JW, Sprenger SH, Gilhuis J, et al. Correlation between localization, age, and chromosomal imbalances in ependymal tumours as detected by CGH. J Pathol 2002;197:238-244.
34. Kramer DL, Parmiter AH, Rorke LB, et al. Molecular cytogenetic studies of pediatric ependymomas. J Neurooncol 1998;37:25-33.
35. Korshunov A, Golanov A, Timirgaz V. p14ARF protein (FL-132) immunoreactivity in intracranial ependymomas and its prognostic significance: an analysis of 103 cases. Acta Neuropathol (Berl) 2001;102:271-277.
36. Scheu S, Bruderlein S, Eicker M, et al. Low frequency of chromosomal imbalances in anaplastic ependymomas as detected by comparative genomic hybridization. Brain Pathol 2001;11:133-143.
37. Ward S, Harding B, Wilkins P, et al. Gain of 1q and loss of 22 are the most common changes detected by comparative genomic hybridisation in paediatric ependymoma. Genes Chromosomes Cancer 2001;32:59-66.